1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Celyad Oncology SA
  6. News
  7. Most relevant
    CYAD   BE0974260896

CELYAD ONCOLOGY SA

(CYAD)
  Report
Real-time Quote. Real-time Euronext Bruxelles - 05/16 03:54:36 am
1.63 EUR   -0.61%
05/06Celyad Oncology SA Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/05CELYAD ONCOLOGY SA : 1st quarter results
CO
05/05CELYAD ONCOLOGY SA : Proxy Statments
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about CELYAD ONCOLOGY SA
05/06Celyad Oncology SA Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
03/25TRANSCRIPT : Celyad Oncology SA, 2021 Earnings Call, Mar 25, 2022
CI
03/25CELYAD ONCOLOGY : Reports Full Year 2021 Financial Results and Recent Business Highlights ..
PU
03/25CELYAD ONCOLOGY : Letter to Shareholders – March 2022
PU
03/24Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/24Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights
AQ
03/17CELYAD ONCOLOGY : to Announce Full Year 2021 Financial Results and Host Conference Call
PU
03/02Celyad Says FDA Places Early-Stage Colorectal Cancer Trial on Clinical Hold
MT
03/02Celyad Oncology Slips 6% on US FDA's Clinical Hold on Colorectal Cancer Treatment Trial
MT
03/02Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial
AQ
03/02Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial
CI
03/01GLOBAL MARKETS LIVE : Bayer, HP, Shell, Toshiba, Citigroup...
02/28HC Wainwright Downgrades Celyad Oncology Neutral From Buy, Shares Plunge 12% at Midday ..
MT
02/28CELYAD ONCOLOGY : Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial - Form 6-K
PU
02/28Celyad Pauses Early-Stage Colorectal Cancer Trial Amid Safety Issues
MT
02/28Celyad Oncology SA Announces Voluntary Pause of CYAD-101-002 Phase 1B Trial
CI
02/28Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial
AQ
02/02CELYAD ONCOLOGY : Summary Note – Listing Prospectus
PU
02/02CELYAD ONCOLOGY : Securities Note
PU
01/31Celyad Oncology Announces February 2022 Conference Schedule
AQ
01/12CELYAD ONCOLOGY : Provides Outlook for 2022 - Form 6-K
PU
01/12Celyad Oncology SA Announces Program Update and Anticipated Milestones for 2022
CI
01/11Wells Fargo Adjusts Celyad Oncology's Price Target to $11 from $20, Keeps Overweight Ra..
MT
2021Celyad Oncology Announces January 2022 Conference Schedule
AQ
2021Transparency notification received from Tolefi SA and related persons (Article 14 ž1 of..
AQ
2021Celyad Oncology - Transparency notification received from Fortress Investment Group LLC
AQ
2021Celyad Oncology Doses First Patient in Trial of Colorectal Cancer Treatment
MT
2021Celyad Oncology Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial
AQ
2021Celyad Oncology SA Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial
CI
2021CELYAD ONCOLOGY : Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Me..
PU
2021CELYAD ONCOLOGY : Transparency Notification Fortress Investment Group LLC
PU
2021TRANSCRIPT : Celyad Oncology SA - Special Call
CI
2021Celyad Oncology SA Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annua..
CI
2021GLOBAL MARKETS LIVE : Apple, Volkswagen, Uber, Rolls-Royce, Gamestop...
2021Celyad Oncology Concludes $33 Million Private Placement
MT
2021Celyad Oncology Closes $32.5 Million Share Sale to Fortress Investment Affiliate
MT
2021CELYAD ONCOLOGY : Announces Closing of $32.5 Million Private Placement with Fortress Inves..
PU
2021Celyad Oncology Announces Closing of $32.5 Million Private Placement with Fortress Inve..
AQ
2021Celyad Oncology SA announced that it has received €28.73 million in funding from F..
CI
2021Celyad Oncology Announces $32.5 Million Private Placement with Fortress
AQ
2021Health Care Stocks Drifting Lower Ahead of Weekend
MT
2021Health Care Stocks Inching Lower But Outperform Most Industry Sectors
MT
2021Top Midday Gainers
MT
2021CELYAD ONCOLOGY : Announces $32.5 Million Private Placement with Fortress Investment Group..
PU
2021Wall Street Set for Narrow Gains, US Unemployment Rate Falls in November
MT
2021Health Care Stocks Rise in Premarket Friday
MT
2021Top Premarket Gainers
MT
2021Celyad Oncology Shares Surge on $32.5 Million Placement
DJ
2021Celyad Secures $32.5 Million Equity Investment From Fortress
MT
2021Celyad Oncology to Raise $33 Million by Issuing 29% Stake to Fortress
MT
2021Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Grou..
AQ
2021Celyad Oncology SA announced that it expects to receive €28.73 million in funding ..
CI
2021CELYAD ONCOLOGY : Coordinated Articles of Association
PU
2021Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highl..
PU
2021Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highl..
AQ
2021Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highl..
CI
2021GLOBAL MARKETS LIVE : Daimler, Delivery Hero, Foxconn, China Evergrande, Kraft Heinz...
2021Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business High..
AQ
2021Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business High..
PU
2021Celyad Oncology Announces November 2021 Conference Schedule
PU
2021CELYAD : Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society f..
AQ
2021CELYAD ONCOLOGY SA(ENXTBR : CYAD) dropped from S&P Global BMI Index
CI
2021CELYAD ONCOLOGY : Supplement n░1 to the Registration Document
PU
2021CELYAD ONCOLOGY : announces September 2021 Conference Schedule
PU
2021CELYAD : Oncology Announces September 2021 Conferences Schedule
AQ
2021CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $15 From $17, Ma..
MT
2021TRANSCRIPT : Celyad Oncology SA, H1 2021 Earnings Call, Aug 05, 2021
CI
2021CELYAD ONCOLOGY : Reports First Half 2021 Financial Results and Recent Business Highlights..
PU
2021CELYAD : Oncology Reports First Half 2021 Financial Results and Recent Business Highlights
AQ
2021Celyad Oncology Sa Reports Earnings Results for the Half Year Ended June 30, 2021
CI
2021CELYAD : Oncology to Announce First Half 2021 Financial Results and Host Conference Call
AQ
2021CELYAD ONCOLOGY : Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based..
BU
2021Celyad Oncology SA Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-b..
CI
2021TRANSCRIPT : Celyad Oncology SA - Special Call
CI
2021CELYAD : Oncology to Host Virtual Research & Development Webinar on July 20th
AQ
1  2  3  4  5  6  7Next
Upcoming event on CELYAD ONCOLOGY SA